StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Wednesday morning. The firm issued a sell rating on the stock. Several other research analysts have also recently issued reports on the company. Benchmark dropped their price target on OncoCyte from $9.00 to $5.00 and set a speculative […]
StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note issued to investors on Friday. The firm issued a sell rating on the stock. Several other equities analysts have also weighed in on the company. Benchmark cut their target price on OncoCyte from $9.00 to $5.00 and set a speculative […]
StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Friday. The firm issued a sell rating on the stock. OCX has been the subject of several other reports. Benchmark reduced their price target on OncoCyte from $9.00 to $5.00 and set a speculative buy rating for the […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Saturday. The firm issued a sell rating on the stock. Several other research analysts also recently weighed in on OCX. Needham & Company LLC dropped their target price on shares of OncoCyte from $4.25 to $3.60 and set […]
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock. Other equities research analysts have also issued research reports about the stock. Benchmark reduced their price objective on shares of OncoCyte from $9.00 to $5.00 […]